Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Radiology and Oncology
Volume 56 (2022): Issue 2 (June 2022)
Open Access
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
Simona Borstnar
Simona Borstnar
,
Marketa Palacova
Marketa Palacova
,
Aleksandra Łacko
Aleksandra Łacko
,
Constanta Timcheva
Constanta Timcheva
,
Einav Nili Gal-Yam
Einav Nili Gal-Yam
,
Konstantinos Papazisis
Konstantinos Papazisis
,
Juraj Beniak
Juraj Beniak
,
Pavol Kudela
Pavol Kudela
and
Gábor Rubovszky
Gábor Rubovszky
| May 17, 2022
Radiology and Oncology
Volume 56 (2022): Issue 2 (June 2022)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Research Article
Published Online:
May 17, 2022
Page range:
238 - 247
Received:
Feb 25, 2022
Accepted:
Apr 08, 2022
DOI:
https://doi.org/10.2478/raon-2022-0020
© 2022 Simona Borstnar, Marketa Palacova, Aleksandra Łacko, Constanta Timcheva, Einav Nili Gal-Yam, Konstantinos Papazisis, Juraj Beniak, Pavol Kudela, Gábor Rubovszky, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.